Skip to content
NYSE · X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS · LARGE CAP

Koninklijke Philips NV PHG

11 fiscal years on record · EUR · FY2025 reported · SEC filings only
€17.8B
▼ 1.0% YoY
€895.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Koninklijke Philips N.V. provides integrated solutions that combine imaging systems and advanced clinical software, as well as diagnostic and therapeutic devices and services. Royal Philips' IP portfolio currently consists of approximately 53,000 patent rights, 31,500 trademarks, 159,000 design rights and 3,100 domain names. Its Diagnosis & Treatment business includes Precision Diagnosis, which offers a range of diagnostic imaging products, solutions and services. Its Connected Care business supports healthcare providers across hospital, ambulatory and home settings with advanced monitoring, diagnostics, informatics and sleep therapy solutions. Its Personal Health business enables individual care routines with technology and solutions that support people's long-term health and well-being.

Written from the business description in KONINKLIJKE PHILIPS NV's annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.

Growth

EUR 17.8B
Revenue, FY2025 · full 11-year series below
Revenue €B Net income €B
FY2025 · Revenue 17.8 · Net income 0.9
10B20B
20152018202120242025
Compound annual growth
+0.0%
+0.6%
+0.6%
−5.5%
+3.7%
−6.3%
+3.2%
+0.0%
+0.0%
+0.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

5 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 8.0% · Net 5.0%
5%10%15%-5%
201520202025
ROE
FY2025 · ROE 7.8%
10%20%-5%-10%
201520202025
Three returns, three denominators.

Each EUR of equity produced 8 cents of profit this year.

Cash & shareholders

EUR 0.00
returned in FY2025 · dividends + net buybacks
Net buybacks €B Dividends €B
FY2025 · Dividends · · Net buybacks -0.0
1B2BDividendsNet buybacks
201520172019202120232025

Total assetsEUR 26.9B
EquityEUR 11.0B
CashEUR 2.8B
Gross debtEUR 8.1B
Net debtEUR 5.3B
Current ratio1.32×

Net debt stands at 48% of equity.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · EUR
row low → row highnegative—not applicable◌not available in our data
PHG, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue €B17.818.018.217.817.217.317.118.117.817.416.8
Operating income €B1.40.5−0.1−1.50.61.31.41.71.51.50.7
EBITDA €B2.51.91.10.11.92.72.72.82.52.41.6
Income tax €B0.31.0−0.1−0.1−0.10.20.30.20.30.20.2
Net income €B0.9−0.7−0.5−1.63.31.21.21.11.71.40.6
EPS, diluted €0.93−0.75−0.49−1.693.501.291.251.141.751.560.68
Dividend / sh €0.850.850.850.850.850.850.850.800.800.800.80
Payout %——−161−4623643937455148
ROE %7.8−5.8−3.7−11.625.29.79.59.113.512.05.4

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 53 reconciliationsAUDITED

Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015. Eight checks were skipped: revenue is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityX-Ray Apparatus & Tubes & Related Irradiation Apparatus
Listed onNYSE
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image